183 related articles for article (PubMed ID: 34172541)
1. Evaluation of two population screening programmes for
Cousens NE; Tiller J; Meiser B; Barlow-Stewart K; Rowley S; Ko YA; Mahale S; Campbell IG; Kaur R; Bankier A; Burnett L; Jacobs C; James PA; Trainer A; Neil S; Delatycki MB; Andrews L
BMJ Open; 2021 Jun; 11(6):e041186. PubMed ID: 34172541
[TBL] [Abstract][Full Text] [Related]
2. Population-based
Tiller JM; Cousens NE; Kaur R; Rowley S; Ko YA; Mahale S; Bankier A; Meiser B; Barlow-Stewart K; Burnett L; Jacobs C; James P; Trainer A; Neil S; Campbell IG; Andrews L; Delatycki M
J Med Genet; 2023 Mar; 60(3):265-273. PubMed ID: 36763037
[TBL] [Abstract][Full Text] [Related]
3. Community attitudes towards a Jewish community BRCA1/2 testing program.
Cousens N; Kaur R; Meiser B; Andrews L
Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
[TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
5. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
7. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
Tennen RI; Laskey SB; Koelsch BL; McIntyre MH; Tung JY
Sci Rep; 2020 May; 10(1):7669. PubMed ID: 32376921
[TBL] [Abstract][Full Text] [Related]
8. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
[TBL] [Abstract][Full Text] [Related]
10. Online BRCA1/2 screening in the Australian Jewish community: a qualitative study.
Yuen J; Cousens N; Barlow-Stewart K; O'Shea R; Andrews L
J Community Genet; 2020 Jul; 11(3):291-302. PubMed ID: 31879826
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
12. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
15. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander M; Bankier A; Southey MC; Venter DJ; Hopper JL
Breast Cancer Res; 2003; 5(6):R206-16. PubMed ID: 14580256
[TBL] [Abstract][Full Text] [Related]
16. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
17. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
[TBL] [Abstract][Full Text] [Related]
18. Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
Morgan KM; Hamilton JG; Symecko H; Kamara D; Jenkins C; Lester J; Spielman K; Pace LE; Gabriel C; Levin JD; Tejada PR; Braswell A; Marcell V; Wildman T; Devolder B; Baum RC; Block JN; Fesko Y; Boehler K; Howell V; Heitler J; Robson ME; Nathanson KL; Tung N; Karlan BY; Domchek SM; Garber JE; Offit K
Genet Med; 2022 Mar; 24(3):564-575. PubMed ID: 34906490
[TBL] [Abstract][Full Text] [Related]
19. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
Abul-Husn NS; Soper ER; Odgis JA; Cullina S; Bobo D; Moscati A; Rodriguez JE; ; ; Loos RJF; Cho JH; Belbin GM; Suckiel SA; Kenny EE
Genome Med; 2019 Dec; 12(1):2. PubMed ID: 31892343
[TBL] [Abstract][Full Text] [Related]
20. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
